BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wang J, Qi S, Zhu YB, Ding L. Prognostic value of YKL-40 in colorectal carcinoma patients: A meta-analysis. World J Clin Cases 2022; 10(7): 2184-2193 [PMID: 35321165 DOI: 10.12998/wjcc.v10.i7.2184]
URL: https://www.wjgnet.com/2307-8960/full/v10/i7/2184.htm
Number Citing Articles
1
Haihui Yu, Ziyi Wang, Bowen Zhu, Ziheng Jia, Jing Luo, Xiao Han, Hui Chen, Rong Shao. A humanized Anti-YKL-40 antibody inhibits tumor developmentBiochemical Pharmacology 2024; 225: 116335 doi: 10.1016/j.bcp.2024.116335
2
Beibei Hu, Danya Zhao, Lanying Li, Xiaomeng Li, Lijie Ma, Yongshuai Jing, Zhongqiu Li, Shiguo Sun. Review—Different Electrochemical Method Employed for Biomarkers Detection in Colorectal CancerJournal of The Electrochemical Society 2024; 171(3): 037523 doi: 10.1149/1945-7111/ad330d
3
Maurice Zaoui, Mehdi Morel, Lila Louadj, Nathalie Ferrand, Antonin Lamazière, Catherine Uzan, Geoffroy Canlorbe, Michael Atlan, Michèle Sabbah. Adipocytes secretome from normal and tumor breast favor breast cancer invasion by metabolic reprogrammingClinical and Translational Oncology 2022; 25(5): 1389 doi: 10.1007/s12094-022-03035-y
4
Błażej Ochman, Sylwia Mielcarska, Agnieszka Kula, Miriam Dawidowicz, Julia Robotycka, Jerzy Piecuch, Monika Szrot, Sylwia Dzięgielewska-Gęsiak, Małgorzata Muc-Wierzgoń, Dariusz Waniczek, Elżbieta Świętochowska. Do Elevated YKL-40 Levels Drive the Immunosuppressive Tumor Microenvironment in Colorectal Cancer? Assessment of the Association of the Expression of YKL-40, MMP-8, IL17A, and PD-L1 with Coexisting Type 2 Diabetes, Obesity, and Active SmokingCurrent Issues in Molecular Biology 2023; 45(4): 2781 doi: 10.3390/cimb45040182